List of Excipients in Branded Drug INFUVITE ADULT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	INFUVITE ADULT	multiple vitamins injection	54643-5649	ANHYDROUS CITRIC ACID
Sandoz Inc	INFUVITE ADULT	multiple vitamins injection	54643-5649	HYDROCHLORIC ACID
Sandoz Inc	INFUVITE ADULT	multiple vitamins injection	54643-5649	POLYSORBATE 80

INFUVITE ADULT Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 4, 2026

INFUVITE ADULT is an established multiple-vitamin injection used as a component of parenteral nutrition. Its commercial opportunity is not based on new-molecule exclusivity. The main opportunities are formulation modernization, packaging, stability, admixture compatibility, supply reliability, and differentiated hospital-channel products.

The product’s excipient strategy must address four technical constraints: oxidation of vitamins, light sensitivity, compatibility with parenteral nutrition solutions, and the need for sterile multi-dose or single-dose presentation. The strongest commercial concepts are likely to be ready-to-use presentations, lower-overfill formulations, improved container-closure systems, and versions optimized for automated pharmacy compounding.

What is INFUVITE ADULT and how is it regulated?

INFUVITE ADULT is a prescription multiple-vitamin injection administered intravenously after dilution. It is used when oral or enteral vitamin supplementation is impractical or inadequate, including in patients receiving parenteral nutrition.[1]

The product contains water-soluble and fat-soluble vitamins. Its formulation is supplied in a two-vial system because the vitamin combination presents stability and solubility challenges in a single concentrated aqueous solution.

Product characteristic	INFUVITE ADULT profile
Dosage form	Sterile multiple-vitamin injection
Route	Intravenous after dilution
Primary use	Vitamin supplementation in parenteral nutrition
Product type	Combination drug product
Active components	Vitamins A, D, E, C, B1, B2, B6, B12, niacinamide, folic acid, biotin and pantothenate
Presentation	Two-vial system requiring reconstitution or admixture
Preservative profile	Labeling should be checked for the specific marketed presentation and lot configuration
Commercial channel	Hospitals, compounding pharmacies, home-infusion providers and parenteral-nutrition services
Regulatory framework	FDA-approved prescription drug product

The two-vial design separates components that have different solubility and degradation profiles. Fat-soluble vitamins require a solubilization strategy, while vitamin C and several B vitamins are susceptible to oxidation, light exposure, pH changes and interactions with trace metals.

What excipients are used in INFUVITE ADULT?

Public product labeling identifies excipients and inactive ingredients used to support solubility, pH control, tonicity, stability and manufacturability. Depending on the vial, formulation and marketed presentation, the relevant excipient classes include polysorbate 80, propylene glycol, glycerin, sodium hydroxide, hydrochloric acid and water for injection.[1]

Exact composition must be evaluated by vial and presentation because the two-vial system does not use identical excipient functions.

Excipient or excipient class	Likely formulation role	Commercial relevance
Polysorbate 80	Solubilizes or disperses fat-soluble vitamins	Potential concern for oxidation, peroxide impurities and compatibility
Propylene glycol	Cosolvent for poorly water-soluble components	Supports concentration but may affect tolerability and labeling
Glycerin	Solvent, tonicity modifier and viscosity control	May assist solubility and product handling
Hydrochloric acid	pH adjustment	Controls vitamin stability and compatibility
Sodium hydroxide	pH adjustment	Balances acidity and supports target pH
Water for injection	Vehicle	Determines dilution, sterility and container requirements

The commercial value of an excipient strategy lies less in the identity of a single inactive ingredient than in the interaction among excipients, vitamin concentration, oxygen exposure, light transmission, container materials and administration conditions.

Why is the excipient strategy technically difficult?

Fat-soluble vitamin solubilization

Vitamins A, D and E have limited aqueous solubility. Polysorbate 80, propylene glycol and glycerin can support incorporation into an injectable system, but each adds development and control requirements.

A replacement surfactant must preserve:

• Solubility after dilution
• Physical stability
• Low particulate formation
• Low peroxide and aldehyde burden
• Compatibility with parenteral nutrition emulsions
• Sterility and endotoxin specifications
• Acceptable local and systemic tolerability

A formulation that eliminates polysorbate 80 but increases oxidation or precipitation would not create a commercial advantage.

Oxidation control

Vitamin C is especially sensitive to oxidation. Riboflavin and other components can also degrade under light exposure. Oxidation may be driven by dissolved oxygen, headspace oxygen, trace metals, light, elevated temperature and excipient impurities.

High-value formulation controls include:

• Low-oxygen filling
• Nitrogen overlay or inert-gas management
• Low-peroxide surfactant grades
• Metal-ion control
• Light-protective vials or secondary packaging
• Oxygen-barrier container systems
• Validated in-use stability after dilution

The most defensible formulation improvement may involve a coordinated container-and-excipient system rather than a new excipient alone.

pH and dilution compatibility

The product is diluted before intravenous administration. The final admixture may contain amino acids, dextrose, electrolytes, trace elements and, in some cases, lipid emulsion. Compatibility can vary by concentration, temperature, container material and storage period.

A commercial formulation should generate data for:

• Common parenteral nutrition concentrations
• Central and peripheral administration conditions
• PVC and non-PVC bags
• Ethylene-vinyl acetate containers
• Multilayer infusion bags
• Syringe and automated compounding systems
• Refrigerated and room-temperature storage
• Immediate-use versus extended-use conditions

Compatibility claims can create practical differentiation even when the active vitamin composition is unchanged.

What formulation opportunities exist for INFUVITE ADULT?

Ready-to-use single-vial presentation

A single-vial product could reduce pharmacy preparation steps and lower reconstitution errors. The technical barrier is maintaining stability for the full vitamin combination in one container.

Potential benefits include:

• Reduced manipulation
• Lower contamination risk
• Faster order fulfillment
• Easier use in home infusion
• Better suitability for automated dispensing
• Lower nursing and pharmacy labor

A single-vial product would need strong stability data, including particulate, potency, sterility, extractables and leachables testing.

Extended-stability formulation

A longer shelf life or longer post-dilution stability period could reduce waste in hospitals and compounding centers. The opportunity is strongest if the formulation supports standard parenteral-nutrition workflows without requiring special storage.

Relevant claims could include:

• Longer refrigerated shelf life
• Longer room-temperature stability
• Longer in-use stability after dilution
• Reduced light-protection requirements
• Lower sensitivity to oxygen exposure

These claims require direct comparative stability data and may support patent protection if linked to a defined excipient ratio, oxygen-control process or packaging configuration.

Low-surfactant or surfactant-free formulation

Surfactant reduction can appeal to hospitals seeking simpler inactive-ingredient profiles. The risk is that removing polysorbate 80 may impair vitamin E or vitamin A solubilization.

Potential replacement approaches include:

• Alternative nonionic surfactants
• Mixed surfactant systems
• Cyclodextrin-based solubilization
• Lipid or emulsion-based delivery
• Solubilizing cosolvent combinations
• Nanodispersed or micellar systems

Each approach creates a different regulatory and manufacturing profile. A new delivery system may provide stronger patentability but also increase development cost and regulatory complexity.

Preservative-free, single-dose packaging

Hospitals increasingly favor single-dose systems that minimize preservative exposure and reduce microbial-risk management. Infuvite Adult is already used in an institutional setting where sterile compounding controls are central, so packaging improvements may produce more value than a change in active composition.

Potential formats include:

• Ready-to-use glass vials
• Polymer vials with low extractables
• Prefilled syringes
• Unit-dose ampoules
• Dual-chamber containers
• Pharmacy-dispensing cartridges

The most commercially practical route is likely an improved vial or dual-chamber system rather than a prefilled syringe, because vitamin admixtures often require downstream dilution.

What patent protection could cover an INFUVITE ADULT reformulation?

The original vitamin combination is old and unlikely to support meaningful new-molecule exclusivity. New protection would need to focus on formulation, packaging, process or use claims.

Formulation patents

A formulation patent could cover:

• A defined surfactant-to-vitamin ratio
• A specific combination of polysorbate, cosolvent and tonicity modifier
• A low-peroxide excipient system
• A pH range that improves vitamin retention
• A metal-chelating strategy
• A single-vial composition with specified stability
• A concentrated formulation for automated compounding

Broad claims covering vitamin mixtures alone would face substantial prior-art risk. Narrow claims tied to measured stability results, impurity thresholds or unusual compatibility properties would be stronger.

Method-of-use patents

Method claims could address:

• Administration through a defined parenteral-nutrition regimen
• Use in a specified patient population
• Use with a particular amino-acid or dextrose concentration
• A dosing or storage method that preserves vitamin potency
• Use in home parenteral nutrition

Method-of-use protection is less likely to block all competing multiple-vitamin injections. Its commercial value depends on whether the claim covers a standard hospital protocol or a differentiated clinical workflow.

Manufacturing and process patents

Process claims may cover:

• Low-oxygen filling
• Inert-gas management
• Sequential addition of vitamins
• Controlled-temperature mixing
• Sterile filtration of a vitamin-containing phase
• Aseptic combination of two sterile concentrates
• Use of low-peroxide excipient raw materials

Manufacturing claims are relevant where the product’s stability depends on oxygen, light or trace-metal control. They are harder to detect in an outside manufacturer’s process, which can reduce litigation value.

Container-closure patents

Packaging claims may protect:

• Light-blocking glass or polymer containers
• Oxygen-scavenging secondary packaging
• Dual-chamber vials
• Break-seal systems
• Low-sorption elastomer closures
• Container systems that reduce vitamin adsorption or leachables

For an established injectable, packaging patents can produce meaningful commercial differentiation because hospitals purchase the finished presentation, not merely the active vitamin blend.

When does INFUVITE ADULT lose exclusivity?

INFUVITE ADULT is an established prescription product rather than a recently approved innovative drug. Any original regulatory exclusivity would have expired long ago. The relevant competitive question is therefore not loss of new-drug exclusivity but the presence of current patents, regulatory listing status, manufacturing approvals and market supply.

The FDA Orange Book should be reviewed for current patents and exclusivity associated with the specific applicant and product listing.[2] For an old combination injection, the main barriers to competition are more likely to be:

1. Sterile manufacturing capacity.
2. Vitamin raw-material qualification.
3. Stability and container-closure validation.
4. FDA approval of the abbreviated or applicable regulatory pathway.
5. Hospital contracting and shortage-related purchasing behavior.
6. Reliable supply of multiple vitamins and excipients.

A new entrant may not need to challenge a patent if no blocking patent is listed. If a patent is listed, a Paragraph IV certification could create litigation risk and a potential 30-month stay under the Hatch-Waxman framework.[3]

What is the Orange Book and Paragraph IV status of INFUVITE ADULT?

The Orange Book identifies approved drug products, therapeutic-equivalence information and, where applicable, listed patents and exclusivity periods. Product status must be assessed by exact application number, strength, dosage form, applicant and marketed label.

For INFUVITE ADULT, a competitive diligence review should verify:

Diligence item	Strategic purpose
NDA or application number	Confirms the regulatory product identity
Current applicant	Identifies the responsible sponsor
Patent listings	Determines potential Paragraph IV exposure
Therapeutic-equivalence code	Indicates FDA substitution status where applicable
Discontinued or active status	Separates historical from current products
Label version	Confirms excipient and presentation details
Drug shortage history	Measures supply-driven opportunity
Manufacturing site information	Tests whether capacity is a barrier

No conclusion about current Paragraph IV litigation should be drawn from historical approvals alone. The relevant record is the current FDA listing and federal court docket for any listed patent dispute.

Which companies could compete with INFUVITE ADULT?

Competition comes from several groups:

Multiple-vitamin injection suppliers

Other suppliers of adult parenteral multivitamin products can compete directly on price, availability, vial configuration and hospital contracts. The principal commercial differentiators are often supply continuity and pharmacy labor rather than clinical efficacy.

Parenteral-nutrition manufacturers

Companies that sell amino-acid, dextrose, lipid and total-parenteral-nutrition products can bundle vitamin supply with broader nutrition contracts. This can weaken a standalone multivitamin supplier’s position.

Compounding pharmacies

503B outsourcing facilities and hospital pharmacies may compound vitamin admixtures under applicable federal and state requirements. Their advantage is workflow integration. Their disadvantages include regulatory burden, batch-release obligations and limited scalability.

Specialty injectable manufacturers

An injectable manufacturer with sterile-fill capacity could develop a differentiated presentation using existing vitamin ingredients. The manufacturing barrier is meaningful because the product requires validated aseptic processing and stability control across multiple vitamins.

What commercial opportunities exist for an INFUVITE ADULT competitor?

The most credible opportunities are operational.

Opportunity	Customer value	Development difficulty	Commercial potential
Ready-to-use presentation	Reduces preparation time	High	High
Extended post-dilution stability	Reduces waste	Medium-high	High
Lower-oxygen package	Improves vitamin retention	Medium	Medium-high
Automated-compounding cartridge	Supports pharmacy automation	High	Medium-high
Single-dose unit packaging	Reduces manipulation	Medium	Medium
Surfactant-reduced formulation	Differentiates inactive profile	High	Medium
Smaller vial overfill	Reduces material waste	Medium	Medium
Home-infusion format	Improves portability and handling	Medium-high	Medium-high
Dual-chamber reconstitution system	Simplifies preparation	High	High

Revenue exposure is concentrated in institutional and home-infusion channels. The product is unlikely to command premium pricing solely because the vitamins are chemically identical to older products. A premium requires measurable labor savings, lower waste, lower preparation risk or improved supply reliability.

How strong is the patent estate for an INFUVITE ADULT reformulation?

The legacy product estate is likely weak as a basis for blocking generic or follow-on competition because the vitamin combination and injectable use are longstanding. A new patent estate could be moderate to strong if it protects a technically necessary formulation or container system that competitors cannot easily design around.

Patent strength would depend on:

• Narrowness of the claimed excipient ranges
• Demonstrated stability improvement
• Evidence that the result is unexpected
• Coverage of the marketed presentation
• Freedom to operate around prior vitamin injections
• Ability to detect infringement
• Remaining patent term
• Regulatory linkage through Orange Book listing

A patent covering only a conventional use of polysorbate 80, propylene glycol or glycerin would likely face obviousness challenges. A patent covering a defined low-peroxide system, specific oxygen-control process and measured potency-retention profile would have a stronger technical record.

What regulatory barriers affect a new INFUVITE ADULT product?

A follow-on product must address more than vitamin content. The sponsor must establish pharmaceutical quality, sterility, stability, container compatibility and clinical suitability under the applicable FDA pathway.

Key regulatory risks include:

• Incomplete characterization of degradation products
• Vitamin potency loss during storage
• Particulate formation after dilution
• Incompatibility with parenteral-nutrition emulsions
• Container extractables and leachables
• Surfactant peroxide impurities
• Adsorption to infusion bags or tubing
• Labeling differences that affect substitution
• Manufacturing-site inspection findings
• Inadequate in-use stability data

A formulation that materially changes the delivery system may require a more extensive FDA package than a conventional equivalent. The regulatory advantage lies in keeping the active vitamin composition and route unchanged while improving excipients or packaging within a well-supported product-development strategy.

Key Takeaways

• INFUVITE ADULT is an established multivitamin injection used in parenteral nutrition.
• Its principal formulation challenges are solubilization, oxidation, light sensitivity, pH control and dilution compatibility.
• Relevant excipient classes include polysorbate 80, propylene glycol, glycerin, hydrochloric acid, sodium hydroxide and water for injection.
• The most attractive opportunities are ready-to-use systems, extended stability, improved oxygen control, single-dose packaging and automated-compounding formats.
• Original product exclusivity is not the main commercial barrier. Sterile manufacturing, stability validation, regulatory approval and hospital contracting are more important.
• New patent value would likely arise from defined excipient systems, packaging, manufacturing processes or demonstrated stability advantages.
• A Paragraph IV strategy depends on the current Orange Book record for the specific product and applicant.
• Premium pricing requires operational value, such as reduced pharmacy labor, lower waste or improved supply reliability.

FAQs

Can a competitor use the same vitamin ingredients as INFUVITE ADULT?

Yes. The vitamin ingredients are established substances. A competitor would need to address regulatory approval, formulation performance, sterility, stability, labeling and any active patent claims covering the particular product or presentation.

Is polysorbate 80 the main patent opportunity in INFUVITE ADULT?

No. Polysorbate 80 alone is unlikely to provide a strong product moat. More defensible protection would combine surfactant characteristics with defined vitamin concentrations, impurity limits, oxygen controls, stability results or a specific container system.

Would a ready-to-use INFUVITE ADULT product qualify for premium pricing?

It could, if it reduces preparation labor, waste or contamination risk. The strongest evidence would come from pharmacy workflow studies, lower discard rates, improved preparation time and documented stability after opening or dilution.

Can a 503B outsourcing facility compete directly with INFUVITE ADULT?

A 503B facility may compete in institutional or regional markets, particularly where it provides customized parenteral-nutrition services. Its ability to compete nationally depends on manufacturing scale, compliance, supply reliability and the regulatory status of the product.

What is the best formulation strategy for a new adult parenteral multivitamin?

The strongest practical strategy is usually a stable, low-oxygen, light-protected presentation with validated compatibility across common parenteral-nutrition containers and storage conditions. A single-vial or dual-chamber format can add commercial value if it materially reduces pharmacy handling.

References

1. DailyMed. (n.d.). INFUVITE ADULT: Multiple vitamins injection, for intravenous use. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Patent certifications and 30-month stays. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-patent-certifications-and-30-month-stays

4. U.S. Pharmacopeial Convention. (n.d.). United States Pharmacopeia and National Formulary: General chapters for injectable products and parenteral nutrition. https://www.usp.org

5. U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages-archives-available-fda-interface-discontinued-drug-product-listing**